Research Reference
Bronchogen
Bronchial tetrapeptide bioregulator — lung health (no validated dose)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Bronchogen is a synthetic bronchial tetrapeptide (Ala-Glu-Asp-Leu, or AEDL) from the Khavinson family of peptide bioregulators. It has no validated human dose. Research-chemical vendors and self-reported community sources most commonly describe 20 mg lyophilized vials reconstituted and administered as short subcutaneous or intramuscular courses of roughly 10–20 days.
A critical distinction: the human record invoked for bronchial peptide bioregulators traces to a tissue extract, not to the synthetic Bronchogen research chemical, which is backed only by a small preclinical literature — rat obstructive-lung models and in-vitro bronchial cell studies — from its originating laboratory. Extract and synthetic are different products with different evidence bases.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 20 mg vial. Resulting concentration: 10 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 0.5 mg | 5 units | 0.05 mL | Daily SubQ (10–20 day course)Lower community range |
| 1 mg | 10 units | 0.1 mL | Daily SubQ (10–20 day course)Mid community range |
| 2 mg | 20 units | 0.2 mL | Daily SubQ (10–20 day course)Upper community range |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
For a 20 mg vial with 2 mL bacteriostatic water, the concentration is 10 mg/mL. A 1 mg amount draws to 0.1 mL (~10 units) on a U-100 insulin syringe.
Gently swirl — do not shake. Refrigerate at 2–8°C and discard after 28 days.
Cycling Protocol
Community and research-chem sources describe short courses of roughly 10–20 days, following the Russian bioregulator "course" convention rather than continuous daily use. Daily amounts community-reported around 0.5–2 mg. There is no validated cycle length for the synthetic peptide.
Routes of Administration
Self-reported community protocols describe two injection routes:
- Subcutaneous (SC): The most commonly described route in community sources, using a small insulin syringe into subcutaneous tissue.
- Intramuscular (IM): Also reported in community references, carried over from the injectable convention historically used for the parent bronchial extract.
No route has been validated for synthetic Bronchogen. Vendors sell it labeled for laboratory research only.
Stacking Protocols
Community references sometimes describe running Bronchogen alongside other Khavinson-family short peptides as part of a broader bioregulator course:
| Peptide | Community-Reported Pairing | Purpose | | --- | --- | --- | | Cortagen | Run in the same short course | Another tissue-directed tetrapeptide bioregulator | | Epitalon | Sequential or overlapping courses | Commonly paired in longevity-oriented community stacks |
No stacking protocol for Bronchogen has been validated in humans.
Side Effects & Safety
- No human safety profile has been established for synthetic Bronchogen; it is sold labeled "not for human consumption."
- Injection-site reactions (redness, soreness) are the effects most commonly noted in self-reported community sources
- No controlled adverse-event data exist for the synthetic peptide, so its tolerability and long-term safety are unknown
- The preclinical studies cited did not characterize a human toxicity or side-effect profile
- Sterile technique and reconstitution hygiene are the practical concerns most often raised in community references
Research Basis
There is no clinical dose-finding trial for synthetic Bronchogen. The dose amounts and course lengths circulating in community sources are inherited from the Russian bioregulator tradition — the short, repeatable "course" convention originally applied to injectable tissue extracts — rather than from a study that titrated the synthetic tetrapeptide in people.
The evidence that does exist for the synthetic molecule is small, preclinical, and largely from a single originating laboratory, reporting effects in rat models of chronic obstructive and inflammatory lung injury and on bronchial epithelial cell behavior in culture (PMID 26468022; 30199201; 31808038). Independent Western replication is effectively absent.
The proposed mechanism is Khavinson's gene-expression hypothesis — the idea that very short peptides interact with DNA and modulate transcription in a tissue-directed way — a model demonstrated largely in vitro rather than in human tissue (PMID 25761685; 34834147).